11:42 AM EDT, 10/16/2024 (MT Newswires) -- Champions Oncology ( CSBR ) said Wednesday that it signed a licensing agreement with Weill Cornell Medicine, allowing it to distribute and commercialize the latter's hematological patient-derived xenograft models.

Under the deal, Champions Oncology ( CSBR ) will have exclusive rights to offer services that use Weill Cornell Medicine's xenograft models for a limited time, according to the statement. The company said it will also serve as a repository for the models' distribution to academic institutions globally.

No financial details were disclosed.

Price: 4.45, Change: -0.09, Percent Change: -1.98